A national, anonymous, online survey was administered inviting 3,161 correctional health professionals to examine the associations between facility characteristics and the availability of medications for opioid use disorder (MOUD) in jails and prisons. Responses from 268 participants representing 212 correctional facilities were analyzed. We used multivariate logistic regression to identify associated facility characteristics, and open-ended responses were analyzed using content analysis. Facilities in the Western United States had higher odds of providing MOUD compared with those in the Midwest (adjusted odds ratio [AOR] = 3.67, 95% confidence interval [CI]: 1.28–10.99). Jails had higher odds of offering MOUD than prisons (AOR = 2.13, OR = 0.47, 95% CI: 0.21–0.99). Qualitative analysis revealed key supports for facilitating MOUD implementation and common barriers.
BelenkoS., HillerM., & HamiltonL. (2013). Treating substance use disorders in the criminal justice system. Current Psychiatry Reports, 15(11), 414. 10.1007/s11920-013-0414-z
2.
BellJ., & StrangJ. (2020). Medication treatment of opioid use disorder. Biological Psychiatry, 87(1), 82–88. 10.1016/j.biopsych.2019.06.020
3.
BerkJ., Del PozoB., RichJ. D., & LeeJ. D. (2022). Injecting opioid use disorder treatment in jails and prisons: The potential of extended-release buprenorphine in the carceral setting. Journal of Addiction Medicine, 16(4), 396–398. 10.1097/ADM.0000000000000942
4.
BerkJ., SouthA. M., MartinM., JamesM. E., MillerC., HaberL., & RichJ. (2025). Medication for opioid use disorder service delivery in carceral facilities: Update and summary report. Health & Justice, 13(1), 8. 10.1186/s40352-025-00317-9
5.
Brinkley-RubinsteinL., PetersonM., ClarkeJ., MacmaduA., TruongA., PognonK., ParkerM., MarshallB. D. L., GreenT., MartinR., SteinL., & RichJ. D. (2019). The benefits and implementation challenges of the first state-wide comprehensive medication for addictions program in a unified jail and prison setting. Drug and Alcohol Dependence, 205, 107514. 10.1016/j.drugalcdep.2019.06.016
6.
CherianT., LimS., KatyalM., GoldfeldK. S., McDonaldR., WiewelE., KhanM., KrawczykN., BraunsteinS., MurphyS. M., JalaliA., JengP. J., RosnerZ., MacDonaldR., & LeeJ. D. (2024). Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration. Drug and Alcohol Dependence, 259, 111274. 10.1016/j.drugalcdep.2024.111274
7.
ClarkeJ. G., MartinR. A., GreskoS. A., & RichJ. D. (2018). The first comprehensive program for opioid use disorder in a US statewide correctional system. American Journal of Public Health, 108(10), 1323–1325. 10.2105/AJPH.2018.304666
8.
EloS., KääriäinenM., KansteO., PölkkiT., UtriainenK., & KyngäsH. (2014). Qualitative content analysis: A focus on trustworthiness. Sage Open, 4(1), 2158244014522633. 10.1177/2158244014522633
9.
GelmanA., MengX.-L., & SternH. (1996). Posterior predictive assessment of model fitness via realized discrepancies. Statistica Sinica, 6(4), 733–760. http://www.jstor.org/stable/24306036
10.
GreenT. C., ClarkeJ., Brinkley-RubinsteinL., MarshallB. D. L., Alexander-ScottN., BossR., & RichJ. D. (2018). Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry, 75(4), 405–407. https://dx.org/10.1001/jamapsychiatry.2017.4614
11.
HillK., BodurthaP. J., WinkelmanT. N. A., & HowellB. A. (2024). Postrelease risk of overdose and all-cause death among persons released from jail or prison: Minnesota, March 2020–December 2021. American Journal of Public Health, 114(9), 913–922. 10.2105/AJPH.2024.307723
12.
HsiehH. F., & ShannonS. E. (2005). Three approaches to qualitative content analysis. Qualitative Health Research, 15(9), 1277–1288. 10.1177/1049732305276687
13.
IlogluS., JoudreyP. J., WangE. A., Thornhill, T. A.IV,., & GonsalvesG. (2021). Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis. Drug and Alcohol Dependence, 220, 108534. 10.1016/j.drugalcdep.2021.108534
14.
KramerC., LenzC., SongM., SufrinC., Kennedy-HendricksA., FingerhoodM., BandaraS. N., & SalonerB. (2025). State-mandated opioid use disorder treatment in Maryland jails helped patients recover despite gaps in care. Health Affairs, 44(5), 614–621. 10.1377/hlthaff.2024.01423
15.
KrawczykN., LimS., CherianT., GoldfeldK. S., KatyalM., RiveraB. D., McDonaldR., KhanM., WiewelE., BraunsteinS., MurphyS. M., JalaliA., JengP. J., KutscherE., KhatriU. G., RosnerZ., VailW. L., MacDonaldR., & LeeJ. D. (2024). Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study. Drug and Alcohol Dependence, 261, 111377. 10.1016/j.drugalcdep.2024.111377
16.
LeeJ. D., MaloneM., McDonaldR., ChengA., VasudevanK., TofighiB., GarmentA., PorterB., GoldfeldK. S., MatteoM., MangatJ., KatyalM., GiftosJ., & MacDonaldR. (2021). Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail. JAMA Network Open, 4(9), e2123032. 10.1001/jamanetworkopen.2021.23032
17.
LeeJ. D., McDonaldR., GrossmanE., McNeelyJ., LaskaE., RotrosenJ., & GourevitchM. N. (2015). Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial. Addiction, 110(6), 1008–1014. 10.1111/add.12894
18.
LiangJ., BiG., & ZhanC. (2020). Multinomial and ordinal logistic regression analyses with multi-categorical variables using R. Annals of Translational Medicine, 8(16), 982. 10.21037/atm-2020-57
19.
LimS., CherianT., KatyalM., GoldfeldK. S., McDonaldR., WiewelE., KhanM., KrawczykN., BraunsteinS., MurphyS. M., JalaliA., JengP. J., MacDonaldR., & LeeJ. D. (2023). Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-2017. Addiction, 118(3), 459–467. 10.1111/add.16071
20.
LimS., CherianT., KatyalM., GoldfeldK. S., McDonaldR., WiewelE., KhanM., KrawczykN., BraunsteinS., MurphyS. M., JalaliA., JengP. J., RosnerZ., MacDonaldR., & LeeJ. D. (2024). Jail-based medication for opioid use disorder and patterns of reincarceration and acute care use after release: A sequence analysis. Journal of Substance Use and Addiction Treatment, 158, 209254. 10.1016/j.josat.2023.209254
21.
LiuA., HeH., TuX.M., & TangW. (2023). On testing proportional odds assumptions for proportional odds models. Gen Psychiatr, 27;36(3):e101048. 10.1136/gpsych-2023-101048
MaruschakL., MintonT., & ZengZ. (2023). Opioid use disorder screening and treatment in local jails, 2019. (NCJ 305179).U.S. Department of Justice Bureau of Justice Statistics. Available from: https://bjs.ojp.gov/document/oudstlj19.pdf
24.
MatsumotoA., SantelicesC., EvansE. A., PivovarovaE., StopkaT. J., FergusonW. J., & FriedmannP. D. (2022). Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts. International Journal of Drug Policy, 109, 103823. 10.1016/j.drugpo.2022.103823
National Academies of Sciences, Engineering, and Medicine. (2019). Medications for Opioid Use Disorder Save Lives. National Academies Press. 10.17226/25310
27.
RanapurwalaS., FiggattM., RemchM., BrownC., Brinkley-RubinsteinL., RosenD., CoxM., & ProescholdbellS. (2022). Opioid overdose deaths among formerly incarcerated persons and the general population: North Carolina, 2000–2018. American Journal of Public Health, 112(2), 300–303. https://dx.org/10.2105/ajph.2021.306621
28.
RichJ. D., McKenzieM., LarneyS., WongJ. B., TranL., ClarkeJ., NoskaA., ReddyM., & ZallerN. (2015). Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: A randomised, open-label trial. Lancet, 386(9991), 350–359. https://dx.org/10.1016/S0140-6736(14)62338-2
29.
ScottC. K., DennisM. L., GrellaC. E., MischelA. F., & CarnevaleJ. (2021). The impact of the opioid crisis on U.S. state prison systems. Health Justice, 9(1), 17. https://dx.org/10.1186/s40352-021-00143-9
30.
Substance Abuse and Mental Health Services Administration. (2019). Use of medication-assisted treatment for opioid use disorder in criminal justice settings. (HHS Publication No. PEP19-MATUSECJS). https://www.prisonpolicy.org/scans/samhsa/mat_cj_system.pdf.
31.
TaylorR. M., & MinkovitzC. S. (2021). Warm handoffs for improving client receipt of services: A systematic review. Maternal and Child Health Journal, 25(4), 528–541. 10.1007/s10995-020-03057-4
ValeraP., LauraB., WoodrowW., & ReidA. (2017). “It’s hard to reenter when you’ve been locked out”: Keys to offender reintegration. Journal of Offender Rehabilitation, 56(6), 412–431. 10.1080/10509674.2017.1339159
34.
WagnerN. M., BinswangerI. A., ShetterlyS. M., RinehartD. J., WainK. F., HopferC., & GlanzJ. M. (2021). Development and validation of a prediction model for opioid use disorder among youth. Drug and Alcohol Dependence, 227, 108980. 10.1016/j.drugalcdep.2021.108980
35.
WinkelmanT. N. A., ChangV. W., & BinswangerI. A. (2018). Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Network Open, 1(3), e180558. 10.1001/jamanetworkopen.2018.0558
36.
WuM., ZhaoK., & Fils-AimeF. (2022). Response rates of online surveys in published research: A meta-analysis. Computers in Human Behavior Reports, 7, 100206. 10.1016/j.chbr.2022.100206
